Psychopharmacologia

, Volume 4, Issue 4, pp 302–307 | Cite as

Comparison between imipramine and desipramine in normal subjects and their action in depressive patients

  • W. Pöldinger
Short Communications

Summary

Differences in action between imipramine (Tofranil®) and desipramine (Pertofran®), a metabolite of imipramine, in normal persons and in depressive patients are described. Correlations with the pharmacological findings of each comparative substance are discussed. If the comparison is limited to the therapeutic action, the two substances show rather similar properties, although there are some differences which seem to us important. On the other hand, the two comparative substances differ much more clearly in their effects in healthy subjects, where even opposite effects can be observed. Namely desipramine in the healthy subject shows a rather potent depressor effect and a slow onset of action, whereas in patients the drug has a short latent period and has a certain stimulant effect. Imipramine on the other hand acts rather slowly in patients but more quickly in healthy persons. It has scarcely any stimulant action, either in normal subjects or in depressive patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ban, T. A., and H. E. Lehmann: Clinical trial with desmethylimipramine (G35020), a new antidepressive compound. Canad. med. Ass. J. 86, 22, 1030–1031 (1961).Google Scholar
  2. Battegay, R.: Vergleichende Bewertung antidepressiv wirksamer Psychopharmaka unter besonderer Berücksichtigung von Pertofran (Desmethylimipramin) G 35020. Meeting of the Collegium Internat. Neuro-Psychopharmacologicum, Munich 1962.Google Scholar
  3. Brodie, B., P. Dick, P. Kielholz, W. Pöldinger and W. Theobald: Preliminary pharmacological and clinical results with desmethylimipramine (DMI) G 35020, a metabolite of Tofranil. Psychopharmacologia (Berl.) 2, 6, 467–474 (1961).Google Scholar
  4. Degkwitz, R.: Über die Tofranil-Wirkung bei langfristigen Selbstversuchen. Med. exp. (Basel) 5, 233–238 (1961).Google Scholar
  5. Fevers, C., D. Huthmacher u. H. Reiling: Medizinisch-psychologische Untersuchungen über die Tofranil-Wirkung bei Gesunden und Kranken. Z. Psychother. med. Psychol. 11, 127–142 (1961).PubMedGoogle Scholar
  6. Gillette, J. R., J. V. Dingell, F. Sulser, R. Kuntzman and B. B. Brodie: Isolation from rat brain of a metabolic product, desmethylimipramine, that mediates the antidepressant activity of imipramine (Tofranil). Experientia (Basel) 17, 417–418 (1961).Google Scholar
  7. Grünthal, E.: Untersuchungen über die besondere psychologische Wirkung des Thymoleptikums Tofranil. Psychiat. et Neurol. (Basel) 136, 6, 402–408 (1962).Google Scholar
  8. Herrmann, B., u. R. Pulver: Der Stoffwechsel des Psychopharmakons Tofranil. Arch. int. Pharmacodyn. 126, 454–469 (1960).PubMedGoogle Scholar
  9. — u. R. Pulver: Papierchromatographischer Nachweis von Stoffwechselprodukten des Tofranil. Med. exp. (Basel) 1, 381–383 (1959).Google Scholar
  10. Mann, A. M.: Desmethylimipramine (G 35020) in the treatment of depression: Pilot study in a general hospital and out-patient setting. Canad. med. Ass. J. 86, 11, 495–498 (1962).PubMedGoogle Scholar
  11. Oltman, J. E., and S. Friedman: Preliminary investigation of desmethylimipramine (G 35020). Amer. J. Psychiat. 119, 4, 370–371 (1962).PubMedGoogle Scholar
  12. Pöldinger, W.: Schweiz. Arch. Neurol. Psychiat. 84, 327 (1959).Google Scholar
  13. - 136th Meeting of the Swiss Psychiatric Assoc., Bern 1962.Google Scholar

Copyright information

© Springer-Verlag 1963

Authors and Affiliations

  • W. Pöldinger
    • 1
  1. 1.Cantonal Psychiatric Clinic St. Urban, Canton of LucerneSwitzerland

Personalised recommendations